BR9609335B8 - Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. - Google Patents

Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.

Info

Publication number
BR9609335B8
BR9609335B8 BRPI9609335-8B8A BR9609335A BR9609335B8 BR 9609335 B8 BR9609335 B8 BR 9609335B8 BR 9609335 A BR9609335 A BR 9609335A BR 9609335 B8 BR9609335 B8 BR 9609335B8
Authority
BR
Brazil
Prior art keywords
residue
ala
amino acid
well
same
Prior art date
Application number
BRPI9609335-8B8A
Other languages
English (en)
Other versions
BR9609335B1 (pt
BR9609335A (pt
Inventor
Rainer Albert
Wilfried Bauer
Christian Bruns
Nagarajan Chandramouli
Ian Lewis
Gisbert Weckbecker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9609335(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9513224.7A external-priority patent/GB9513224D0/en
Priority claimed from GBGB9600429.6A external-priority patent/GB9600429D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9609335A publication Critical patent/BR9609335A/pt
Publication of BR9609335B1 publication Critical patent/BR9609335B1/pt
Publication of BR9609335B8 publication Critical patent/BR9609335B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
BRPI9609335-8B8A 1995-06-29 1996-06-28 Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. BR9609335B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513224.7A GB9513224D0 (en) 1995-06-29 1995-06-29 Organic compounds
GBGB9600429.6A GB9600429D0 (en) 1996-01-10 1996-01-10 Organic compounds
PCT/EP1996/002840 WO1997001579A2 (en) 1995-06-29 1996-06-28 Somatostatin peptides

Publications (3)

Publication Number Publication Date
BR9609335A BR9609335A (pt) 1999-05-25
BR9609335B1 BR9609335B1 (pt) 2009-08-11
BR9609335B8 true BR9609335B8 (pt) 2014-10-07

Family

ID=26307298

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9609335-8B8A BR9609335B8 (pt) 1995-06-29 1996-06-28 Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.

Country Status (24)

Country Link
US (1) US6225284B1 (pt)
EP (1) EP0835263B9 (pt)
JP (2) JP3445796B2 (pt)
KR (1) KR100454664B1 (pt)
CN (1) CN1156492C (pt)
AT (1) ATE210152T1 (pt)
AU (1) AU714447B2 (pt)
BR (1) BR9609335B8 (pt)
CA (1) CA2222524C (pt)
CZ (1) CZ297381B6 (pt)
DE (1) DE69617687T2 (pt)
DK (1) DK0835263T3 (pt)
ES (1) ES2169251T3 (pt)
HU (1) HU228984B1 (pt)
IL (1) IL122243A (pt)
MY (1) MY147327A (pt)
NO (1) NO317867B1 (pt)
NZ (1) NZ313147A (pt)
PL (1) PL184947B1 (pt)
PT (1) PT835263E (pt)
SK (1) SK284087B6 (pt)
TR (1) TR199701718T1 (pt)
TW (1) TW491854B (pt)
WO (1) WO1997001579A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (ja) * 1997-03-06 1998-09-22 American Cyanamid Co ソマトスタチン拮抗薬として有用なペプチド
EP0981364B1 (en) 1997-05-13 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Method and compositions for treating hyperlipidemia
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
ES2202864T3 (es) 1997-05-13 2004-04-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Agonistas de la somatostatina para disminuir el peso corporal.
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
JP2003514867A (ja) * 1999-11-29 2003-04-22 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ環状類似物
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
ES2325880T3 (es) 2001-06-08 2009-09-23 Ipsen Pharma Analogos quimericos de somatostatina-dopamina.
WO2003057214A1 (en) * 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
EP1478406B1 (en) * 2002-02-27 2011-01-05 PharmaIN Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
EP1506000B9 (en) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003299519A1 (en) * 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
NZ540363A (en) * 2002-11-25 2007-11-30 Attenuon Llc Peptides which target tumor and endothelial cells, compositions and uses thereof
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
DE60331770D1 (de) * 2002-12-12 2010-04-29 Novartis Ag Prozess für die herstellung von peptiden, die eine 4-hydorxy-prolin substruktur enthalten
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AU2004232314B2 (en) 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) * 2005-04-28 2006-11-02 Schering Ag Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
AR067442A1 (es) * 2007-06-29 2009-10-14 Gilead Sciences Inc Compuestos antivirales
RU2523416C2 (ru) 2007-11-28 2014-07-20 Новартис Аг Применение аналогов соматостатина при менингиоме
CA2702940C (en) * 2007-12-03 2016-09-13 Andrea Vitali New non-selective somatostatin analogues
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
ES2399651T3 (es) * 2008-07-08 2013-04-02 Novartis Ag Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
KR20110114582A (ko) * 2008-12-19 2011-10-19 길리애드 사이언시즈, 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제
EP2380596A1 (en) * 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
WO2016097962A1 (en) 2014-12-19 2016-06-23 Auro Peptides Ltd A process for the preparation of pasireotide
CN106432429A (zh) * 2016-10-24 2017-02-22 合肥国肽生物科技有限公司 一种帕西瑞肽的合成方法
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) * 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
EP0720621B1 (en) * 1993-06-23 2001-02-07 Diatide, Inc. Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
CZ419697A3 (cs) 1998-05-13
PL184947B1 (pl) 2003-01-31
WO1997001579A2 (en) 1997-01-16
NO976064D0 (no) 1997-12-23
CA2222524A1 (en) 1997-01-16
CZ297381B6 (cs) 2006-11-15
CN1189166A (zh) 1998-07-29
DK0835263T3 (da) 2002-04-02
ATE210152T1 (de) 2001-12-15
HUP9901455A2 (hu) 1999-09-28
MY147327A (en) 2012-11-30
US6225284B1 (en) 2001-05-01
CN1156492C (zh) 2004-07-07
NO317867B1 (no) 2004-12-27
KR19990028480A (ko) 1999-04-15
JP3445796B2 (ja) 2003-09-08
JPH11506108A (ja) 1999-06-02
HU228984B1 (en) 2013-07-29
EP0835263B9 (en) 2002-07-24
NZ313147A (en) 1999-11-29
HUP9901455A3 (en) 2000-11-28
BR9609335B1 (pt) 2009-08-11
IL122243A0 (en) 1998-04-05
WO1997001579A3 (en) 1997-02-27
AU714447B2 (en) 2000-01-06
BR9609335A (pt) 1999-05-25
TW491854B (en) 2002-06-21
TR199701718T1 (xx) 1998-05-21
DE69617687D1 (de) 2002-01-17
DE69617687T2 (de) 2002-08-22
SK284087B6 (sk) 2004-09-08
NO976064L (no) 1998-02-16
EP0835263A2 (en) 1998-04-15
IL122243A (en) 2005-09-25
AU6515096A (en) 1997-01-30
PT835263E (pt) 2002-04-29
EP0835263B1 (en) 2001-12-05
ES2169251T3 (es) 2002-07-01
CA2222524C (en) 2010-01-26
JP2003104998A (ja) 2003-04-09
KR100454664B1 (ko) 2005-09-12
PL323943A1 (en) 1998-04-27
SK177097A3 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
BR9609335B8 (pt) Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos.
Eyre et al. Collagen type IX: evidence for covalent linkages to type II collagen in cartilage
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
ATE245659T1 (de) Insulinabkömmlinge
ES2134669T3 (es) Insulinas lys (b28). analogos de la insulina humana.
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
KR870002163A (ko) 펩티드의 제조방법
KR840007569A (ko) Grf 유사체 펩티드의 제법
HRP20090571T1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
NZ222466A (en) Hexa to deca peptides capable of stimulating the proliferation of myelopoietic stem cells
ATE146188T1 (de) Substituierungsanaloge von magaininpeptiden
MX9709962A (es) Peptidos de somatostatina.
ECSP961798A (es) Peptidos de somatostatina
KNORR et al. [B17-D-Leucine] Insulin and [B17-Norleucine] Insulin: synthesis and biological properties
DK119391A (da) Humaninsulinanaloger

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/09/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.062008/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132270-62.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:NIPPON KAYAKU KABUSHIKI KAISHA, NOVARTIS AG, NOVARTIS SA, NOVARTISINS, NOVARTIS CONSUMER HEALTH S.A.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.104054/2014 SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO NO 2014.51.01.001852-6 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU: NOVARTIS AG E OUTROS DECISAO: ANTECIPO OS EFEITOS DA TUTELA, A FIM DE DETERMINAR A IMEDIATA READEQUACAO DO PRAZO DE VIGENCIA DA PATENTE PI9609335-8 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, NOS TERMOS DO PARAGRAFO UNICO DO ART. 229 C/C O CAPUT DO ART. 40 DA LPI, CONFORME TABELA A SEGUIR: NOME DO TITULAR: NOVARTIS AG -PATENTE: PI9609335-8-PRAZO DE VIGENCIA:28/06/2016

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2020 DE 22/09/2009, POR DETERMINACAO DA 13A VARA FEDERAL DO RIO DE JANEIRO, QUANTOAO PRAZO DE VALIDADE.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.104054/2014 - SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO NO0001852-02.2014.4.02.5101 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI F REU: NOVARTIS AG E OUTROS DECISAO: DETERMINAR EM DEFINITIVO ADEQUACAO DO PRAZO DE VIGENCIA DA PATENTE PI9609335-8 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, CONFORME TABELA ABAIXO: TITULAR: NOVARTIS AG PI9609335-8 PRAZO DE VIGENCIA: 28/06/2016

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 28/06/2016